Day: December 9, 2021

What is the outlook for the NAB (ASX:NAB) share price in 2022?

watch

Shares in banking giant National Australia Bank Ltd. (ASX: NAB) edged higher on Thursday to finish trading at $28.69, up 0.21%.

It’s been a fairly stable year for the NAB share price, as volatility has been constrained and periods of drawdown have been short-lived.

Each downtick in price action has seen NAB springboard off the bottom and climb to new 52-week highs in the days to weeks afterwards.

As such, shareholders have enjoyed a 22% upside in the last 12 months, after shares have rallied a further 27% this year to date, beating the benchmark S&P/ASX 200 Index (ASX: XJO)’s return of 10% in the last year.

With this in mind, we ask – what’s the outlook for NAB investors in 2022? Read on to see what the experts are saying.

What can NAB investors expect in 2022?

In terms of financial performance, data provided by Bloomberg Intelligence reveals that the majority of analysts expect NAB to deliver $17.63 billion in revenue in FY22, which could carry through to $6.4 billion in net profit after tax (NPAT).

This calls for a net margin of 36.5%, and earnings per share (EPS) of $1.95 in FY22. Compared to FY21, that’s a growth of 3.6%. At present, the bank’s total capital ratio is 18.91% as of FY21.

The team at JP Morgan reckon there are plenty of legs left in the NAB share price next year and retain an overweight rating on the stock.

JP Morgan’s stance is reflective of what it deems as NAB’s “stronger-than-peer revenue growth prospects more than offsetting uncertainty on potential enforcement action from AUSTRAC on AML”.

Not only that, the broker notes NAB’s stronger revenue profile versus its peers, and that this reflects NAB’s tilt towards small business banking, which should insulate it from return on equity (ROE) pressures in retail banking.

Whilst it acknowledges that there are still headwinds on the horizon for NAB, JP Morgan has these factored into its forecasts and still sees NAB’s “pre-provision profit growth outstripping peers”.

As such it has a December 2022 price target of $31.40 on the share price, a number which NAB is gradually encroaching on, given its current trajectory.

What is the sentiment on NAB for 2022?

Jarden Securities is equally as bullish on the banking sector and likes the recent focus of Aussie banks in capital management, and cost efficiency over the medium term. It values NAB at $31 a share.

Jefferies is the most bullish on NAB, folding in a $32.60 price target on the share, whereas JP Morgan is a close second.

Goldman Sachs, Bell Potter, Jarden and Barrenjoey each value NAB at $31 a share, whereas Macquarie reckons the bank is worth $30.50 per share.

In fact, the bulk of analysts covering NAB – 62.5% to be exact – have NAB as a buy. The average price target of the analyst group is $30.14, according to the list provided by Bloomberg Intelligence.

With this in mind, taking the wisdom of the crowd, this average figure implies an upside potential of 4.7% at the time of writing.

Hence, the sentiment is bullish on NAB shares and going by what these experts think, it may be a period of marginal growth in FY22 for the company’s share price. However, do note that price targets change often on the back of earnings results, and this may very well be the case for NAB early in FY22.

The post What is the outlook for the NAB (ASX:NAB) share price in 2022? appeared first on The Motley Fool Australia.

Should you invest $1,000 in National Australia Bank right now?

Before you consider National Australia Bank, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and National Australia Bank wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

The author has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/307OhbJ

Why did Pengana Private Equity Trust (ASX:PE1) shares jump 8% today?

happy group of people

The S&P/ASX 200 Index (ASX: XJO) ended up having a bit of a disappointing day of trading this Thursday. The ASX 200 ended up finishing at 7,384.5 points, down 0.28%.

But one ASX share was a far more pleasing spectacle to watch. That was the Pengana Private Equity Trust (ASX: PE1) share price. Pengana Private Equity shares ended up finishing the trading day at $1.66 each, up a very pleasing 7.82%. That came after closing at $1.54 a share yesterday and opening at $1.55 this morning.

What’s more is that the $1.66 share price that Pengana Private Equity finished at was both a new 52-week and all-time high for the fund.

Pengana Private Equity is a fund that invests in private equity (companies not traded on a public share market). It has returned an average performance of 13.3% per annum since its inception (April 2019) and targets a 4% dividend yield.

So what was pushing this trust up so convincingly today?

A new high for Pengana Private Equity shares

Well, it seems that a monthly investment update could be to thank. Pengana put out this ASX notice this morning before market open.

It informed the markets that the Pengana Private Equity Trust returned 9.3% over the month of November. That’s objectively an impressive performance for just one month. Especially considering the S&P/ASX 200 Index (ASX: XJO) actually went backwards by close to 1% over the same period.

So how did the Trust make such pleasing bank during November? Well, Pengana cited its investments in Project Rambler, Deliverr and the successful initial public offering (IPO) of the US carmaker Rivian Automotive Inc (NASDAQ: RIVN). On the latter, Pengana stated the following:

We had exposure to the private equity and a convertible security of Rivian, both of which are now held in the company’s public equity. As a participant in the convertible security, we were entitled to additional IPO shares, which we purchased at the IPO price and exited at a material profit shortly after the initial purchase.

The Amazon-backed Rivian made headlines last month when it rocketed nearly 30% on its first day of trading. So you can see how Pengana Private Equity Trust might have made a quid on this investment.

The post Why did Pengana Private Equity Trust (ASX:PE1) shares jump 8% today? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Pengana Private Equity Trust right now?

Before you consider Pengana Private Equity Trust, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pengana Private Equity Trust wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3IwwSLb

Why did the AGL share price outperform the ASX 200 today?

Young female AGL investor leans back in her desk chair feeling relieved after the AGL share price soared today

The S&P/ASX 200 Index (ASX: XJO) had a pretty poor day on Thursday, closing 0.28% down to 7,384.50. But one ASX 200 share left the index in the dust. That was none other than AGL Energy Limited (ASX: AGL).

Yes, AGL shares went up by a very healthy 4.66% on Thursday to finish the session at $5.84. This means the AGL share price is now trading 14.5% above its 20-year low of $5.10, which it descended to back on 16 November.

A partnership with Fortescue Future Industries?

So why did AGL shares have such a robust day? Especially in the face of an anaemic broader market?

Well, there was no news or announcements out of AGL today, so we can’t say for sure. However, these gains could possibly be linked to the news out yesterday.

As we reported, AGL told investors that it has signed a memorandum of understanding (MOU) with Fortescue Future Industries. This could result in AGL transforming its Liddell and Bayswater coal-fired power stations into green hydrogen hubs.

The MOU will result in a 12-month feasibility study which will “map key operational and commercial plans for the project”.

Fortescue Future Industries is the hydrogen venture started by Fortescue Metals Group Limited (ASX: FMG) boss Dr Andrew Forrest AO. It aims to produce 15 million tonnes of green hydrogen annually by 2030 using renewable energy.

AGL aims to close Liddell and Bayswater by 2023 and 2025 respectively. In their place, AGL is hoping to use renewable energy and large-scale batteries — ideally in conjunction with Fortescue Future Industries.

AGL share price snapshot

AGL’s long-suffering shareholders will no doubt welcome today’s price gains. AGL has seen its market capitalisation decimated over the past 5 years. This has occurred due to poor energy market profitability and concern over AGL’s emissions-intensive power generation assets.

Despite the recent rally, the AGL share price is still down a nasty 51.9% year to date in 2021. It’s also down close to 80% from the all-time highs of roughly $28 a share that we saw back in 2017.

At the current AGL share price, the company has a market capitalisation of $3.84 billion with a trailing dividend yield of 11.15%.

The post Why did the AGL share price outperform the ASX 200 today? appeared first on The Motley Fool Australia.

Should you invest $1,000 in AGL right now?

Before you consider AGL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and AGL wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/31HD1TV

Argenica (ASX:AGN) share price leapt 12% on US patent news today

four excited doctors with their hands in the air

The Argenica Therapeutics Ltd (ASX: AGN) share price was rocketing today after the company released positive news on a US patent.

The biotechnology company’s shares were up 12.36% at the close, trading at 75 cents.

Argenica is working on new therapeutics to protect the brain after a patient suffers a stroke and other brain injuries.

Why is the Argenica share price up today?

Investors appeared to welcome news the company will be granted a US patent for its lead drug candidate ARG-007.

Argenica said this meant it would be able to use ARG-007 to treat people with stroke, traumatic brain injury and hypoxic-ischaemic encephalopathy (HIE). HIE is a condition that arises from not having enough oxygen or blood flow to the brain.

Argenica now plans to spearhead the drug’s commercialisation in the lucrative United States market.

The company advised it was given official “notice of allowance” for the patent, with the patent being formally granted within months.

The patent claim also covers the drug’s use for other diseases including multiple sclerosis, Parkinson’s disease, Huntington’s disease and epilepsy.

Comment from management

Argenica CEO Dr Liz Dallimore welcomed the announcement, saying:

The granting of this patent will strengthen our ability to enter into commercial negotiations with US pharmaceutical companies in the future.

The allowance of the claims in Argenica’s US patent are essential to potentially commercialising ARG-007 in our lead applications of stroke, TBI and HIE in the US.

Argenica Therapeutics share price snapshot

The Argenica share price has shot up in 2021, up 275%. The company listed on the ASX in June.

Over the past month, Argenica shares are up 50%. The company has a market capitalisation of about $35 million based on the current share price.

The post Argenica (ASX:AGN) share price leapt 12% on US patent news today appeared first on The Motley Fool Australia.

Should you invest $1,000 in Argenica Therapeutics right now?

Before you consider Argenica Therapeutics, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Argenica Therapeutics wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3y81ePr